Interest in Electronic Cigarettes for Smoking Cessation Among Adults With Opioid Use Disorder in Buprenorphine Treatment: A Mixed-Methods Investigation

被引:5
作者
Streck, Joanna M. [1 ,2 ,3 ,4 ]
Regan, Susan [1 ,2 ]
Neil, Jordan [4 ,5 ]
Kalkhoran, Sara [1 ,2 ]
Gupta, Priya S. [1 ,2 ]
Bearnot, Benjamin [1 ,2 ]
Coker, Faith K. [1 ,2 ]
Kalagher, Kelly M. [1 ,2 ,3 ]
Park, Elyse [1 ,2 ]
Wakeman, Sarah [1 ,2 ]
Rigotti, Nancy A. [1 ,2 ,4 ]
机构
[1] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Div Gen Internal, Med Dept Med, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Family & Prevent Med, Oklahoma City, OK USA
[5] Stephenson Canc Ctr, Hlth Promot Res Ctr, Oklahoma City, OK USA
关键词
TOBACCO USE; METHADONE;
D O I
10.1093/ntr/ntab259
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction Individuals in treatment for opioid use disorder (OUD) have high smoking rates and limited success with Food and Drug Administration (FDA)-approved cessation aids, suggesting need for novel approaches. Electronic cigarettes (e-cigarettes) might benefit this population, but e-cigarettes' acceptability for tobacco reduction or cessation among smokers in OUD treatment is not known. Methods A cross-sectional mixed-methods study of 222 adults in OUD treatment with buprenorphine in the Boston, Massachusetts metropolitan area was conducted in 2020. We used quantitative and qualitative data to investigate individuals' experience with and interest in e-cigarettes and other methods for smoking cessation and assessed factors associated with interest in e-cigarette use. Results One hundred sixty (72%) of the 222 participants were past 30-day cigarette smokers. They most frequently reported having ever used nicotine replacement therapy (NRT; 83%) and e-cigarettes (71%) for smoking cessation and most often indicated interest in using NRT (71%) and e-cigarettes (44%) for future smoking cessation. In multiple logistic regression analysis, interest in using e-cigarettes for future smoking cessation was independently associated with having ever used e-cigarettes for smoking cessation, current e-cigarette use, and perceiving e-cigarettes to be less harmful than cigarettes (ps < .05). In qualitative data, many current vapers/former smokers reported that e-cigarettes had been helpful for quitting cigarettes. For current smokers who currently or formerly vaped, frequently reported challenges in switching to e-cigarettes were concerns about replacing one addiction with another and e-cigarettes not adequately substituting for cigarettes. Conclusions E-cigarettes had a moderate level of acceptability for smoking cessation among cigarette smokers in OUD treatment. More research is warranted to test the efficacy of this approach. Implications Individuals in treatment for opioid use disorder (OUD) have high smoking rates and limited success with existing smoking cessation tools, suggesting a need for novel cessation treatment approaches. In this mixed-methods study of individuals receiving medication treatment for OUD with buprenorphine in Massachusetts in 2020, we found a moderate level of acceptability of e-cigarettes for smoking cessation.
引用
收藏
页码:1134 / 1138
页数:5
相关论文
共 36 条
  • [21] Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
    Breanne E. Biondi
    Brent Vander Wyk
    Esther F. Schlossberg
    Albert Shaw
    Sandra A. Springer
    Addiction Science & Clinical Practice, 17
  • [22] A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions
    Ling, Sara
    Mangaoil, Remar
    Cleverley, Kristin
    Sproule, Beth
    Puts, Martine
    DRUG AND ALCOHOL DEPENDENCE, 2019, 197 : 168 - 182
  • [23] Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
    Biondi, Breanne E.
    Vander Wyk, Brent
    Schlossberg, Esther F.
    Shaw, Albert
    Springer, Sandra A.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2022, 17 (01)
  • [24] Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
    Ker, Sheryl
    Hsu, Jennifer
    Balani, Anisha
    Mukherjee, Sankha Subhra
    Rush, A. John
    Khan, Mehreen
    Elchehabi, Sara
    Huffhines, Seth
    DeMoss, Dustin
    Renteria, Miguel E.
    Sarkar, Joydeep
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 3229 - 3244
  • [25] Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs
    Jaclyn M. W. Hughto
    Abigail Tapper
    Sabrina S. Rapisarda
    Thomas J. Stopka
    Wilson R. Palacios
    Patricia Case
    Joseph Silcox
    Patience Moyo
    Traci C. Green
    Substance Abuse Treatment, Prevention, and Policy, 18
  • [26] Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review
    Shirk, Steven D.
    Ameral, Victoria
    Kraus, Shane W.
    Houchins, Joseph
    Kelly, Megan
    Pugh, Kendra
    Reilly, Erin
    Desai, Nitigna
    JOURNAL OF DUAL DIAGNOSIS, 2021, 17 (03) : 207 - 215
  • [27] Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder
    Monico, Laura B.
    Fletcher, Jesse B.
    Ross, Tyler
    Schwartz, Robert P.
    Fishman, Marc J.
    Gryczynski, Jan
    Mitchell, Shannon Gwin
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 162
  • [28] Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs
    Hughto, Jaclyn M. W.
    Tapper, Abigail
    Rapisarda, Sabrina S.
    Stopka, Thomas J.
    Palacios, Wilson R.
    Case, Patricia
    Silcox, Joseph
    Moyo, Patience
    Green, Traci C.
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2023, 18 (01)
  • [29] Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
    Petrakis, Ismene
    Springer, Sandra A.
    Davis, Cynthia
    Ralevski, Elizabeth
    Gu, Lucy
    Lew, Robert
    Hermos, John
    Nuite, Melynn
    Gordon, Adam J.
    Kosten, Thomas R.
    Nunes, Edward, V
    Rosenheck, Robert
    Saxon, Andrew J.
    Swift, Robert
    Goldberg, Alexa
    Ringer, Robert
    Ferguson, Ryan
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2022, 17 (01)
  • [30] Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives
    Pryce S. Michener
    Elizabeth A. Evans
    Warren J. Ferguson
    Peter D. Friedmann
    Addiction Science & Clinical Practice, 19